Cargando…
Precautions for Patients Taking Aromatase Inhibitors
Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor– or progesterone receptor–positive breast cancer in postmenopausal women. Aromatase is an enzyme that catalyzes the final and rate-limiting step in the biosynthesis of estrogen. Inhibitors of this enzyme are an effect...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848814/ https://www.ncbi.nlm.nih.gov/pubmed/33532117 http://dx.doi.org/10.6004/jadpro.2020.11.2.6 |
_version_ | 1783645206051028992 |
---|---|
author | Heery, Mary Farley, Stephen Sparkman, Rhett Healy, John Eighmy, William Zahrah, George Zelkowitz, Richard |
author_facet | Heery, Mary Farley, Stephen Sparkman, Rhett Healy, John Eighmy, William Zahrah, George Zelkowitz, Richard |
author_sort | Heery, Mary |
collection | PubMed |
description | Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor– or progesterone receptor–positive breast cancer in postmenopausal women. Aromatase is an enzyme that catalyzes the final and rate-limiting step in the biosynthesis of estrogen. Inhibitors of this enzyme are an effective therapy for breast cancer. The benefits of these agents have been clearly shown through various clinical trials, yet adherence may be challenging for some patients due to issues of drug interactions, proper first dose education, and adverse effects. Education to prevent and treat adverse effects is of the utmost importance to promote adherence. |
format | Online Article Text |
id | pubmed-7848814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Harborside Press LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-78488142021-02-01 Precautions for Patients Taking Aromatase Inhibitors Heery, Mary Farley, Stephen Sparkman, Rhett Healy, John Eighmy, William Zahrah, George Zelkowitz, Richard J Adv Pract Oncol Practice Matters Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor– or progesterone receptor–positive breast cancer in postmenopausal women. Aromatase is an enzyme that catalyzes the final and rate-limiting step in the biosynthesis of estrogen. Inhibitors of this enzyme are an effective therapy for breast cancer. The benefits of these agents have been clearly shown through various clinical trials, yet adherence may be challenging for some patients due to issues of drug interactions, proper first dose education, and adverse effects. Education to prevent and treat adverse effects is of the utmost importance to promote adherence. Harborside Press LLC 2020-03 2020-03-01 /pmc/articles/PMC7848814/ /pubmed/33532117 http://dx.doi.org/10.6004/jadpro.2020.11.2.6 Text en © 2020 Harborside™ http://creativecommons.org/licenses/by-nc-nd/3.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Practice Matters Heery, Mary Farley, Stephen Sparkman, Rhett Healy, John Eighmy, William Zahrah, George Zelkowitz, Richard Precautions for Patients Taking Aromatase Inhibitors |
title | Precautions for Patients Taking Aromatase Inhibitors |
title_full | Precautions for Patients Taking Aromatase Inhibitors |
title_fullStr | Precautions for Patients Taking Aromatase Inhibitors |
title_full_unstemmed | Precautions for Patients Taking Aromatase Inhibitors |
title_short | Precautions for Patients Taking Aromatase Inhibitors |
title_sort | precautions for patients taking aromatase inhibitors |
topic | Practice Matters |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848814/ https://www.ncbi.nlm.nih.gov/pubmed/33532117 http://dx.doi.org/10.6004/jadpro.2020.11.2.6 |
work_keys_str_mv | AT heerymary precautionsforpatientstakingaromataseinhibitors AT farleystephen precautionsforpatientstakingaromataseinhibitors AT sparkmanrhett precautionsforpatientstakingaromataseinhibitors AT healyjohn precautionsforpatientstakingaromataseinhibitors AT eighmywilliam precautionsforpatientstakingaromataseinhibitors AT zahrahgeorge precautionsforpatientstakingaromataseinhibitors AT zelkowitzrichard precautionsforpatientstakingaromataseinhibitors |